Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock

MPM BioVentures 2018 sold $615,777 worth of Entrada Therapeutics stock in a span of four days in late August 2026. The company, which owned 10% of the business, made multiple transactions involving different numbers of shares at varying prices. On August 27, they sold 38,922 shares at an average price of $7.2 per share. The following day, they sold 3,733 shares at $7.01 each, and on August 31, they closed the transactions with a sale of 44,259 shares at $6.99 per share.

After all the sales, MPM BioVentures held roughly 4.23 million shares of the company. Analysts currently view the stock as potentially undervalued, with price targets ranging from $11 to $25. Despite the recent sales, the company's financials show it has more cash on hand than debt. MPM BioVentures is still the 10% owner and director of Entrada Therapeutics.

Meanwhile, the company has received approval to increase the dose in its ELEVATE-45-201 study for Duchenne muscular dystrophy. This progress underscores the company's commitment to advancing its clinical pipeline.